Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database.
Edoardo Francini, Daniel Yick Chin Heng(University of Calgary), Christopher J. Sweeney(The University of Adelaide), Nimira Alimohamed(University of Calgary), Jesús García‐Foncillas(Hospital Universitario Fundación Jiménez Díaz), Alan H. Bryce(Mayo Clinic Hospital), Richard M. Lee‐Ying(Alberta Health Services), Roberto Petrioli(Azienda Ospedaliera Universitaria Senese), Antonio Cigliola(Vita-Salute San Raffaele University), Celestia S. Higano(University of British Columbia), Pier Vitale Nuzzo(Dana-Farber Cancer Institute), Lauren C. Harshman(Dana-Farber Cancer Institute), Guido Francini(University of Siena), Grace Shaw(Dana-Farber Cancer Institute), Irene Moreno, Carmelo Bengala(Ospedale Misericordia - Grosseto), Jaime Rubio(Hospital Universitario Fundación Jiménez Díaz), Francesca Montagnani(University of Siena), Francesca Crivelli(Ospedale degli Infermi), Miguel González-Vélez(Mayo Clinic Hospital)
Cited by 1
Related Papers
The Molecular Taxonomy of Primary Prostate Cancer
|Cell|2015|3.3k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k